- Trials with a EudraCT protocol (18)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
18 result(s) found for: Cervical mucus.
Displaying page 1 of 1.
EudraCT Number: 2022-003219-26 | Sponsor Protocol Number: MR-130A-01-TD-2001 | Start Date*: 2023-01-10 | |||||||||||
Sponsor Name:Mylan Pharmaceuticals, Inc | |||||||||||||
Full Title: An open-label, phase II, dose-finding study of three dose strengths of MR-130A-01 contraceptive transdermal patch containing norelgestromin (NGMN) in healthy pre-menopausal women | |||||||||||||
Medical condition: Investigation of ovulation inhibition for indication of contraception in healthy subjects | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-009177-10 | Sponsor Protocol Number: BAY86-5016/14348 | Start Date*: 2009-04-30 |
Sponsor Name:Bayer HealthCare AG | ||
Full Title: Multicenter, open-label, randomized study to evaluate inhibition of ovulation of two transdermal patch formulations containing 0.55 mg ethinylestradiol and either 1.05 or 2.1 mg gestodene in health... | ||
Medical condition: The trial will be performed in healthy female volunteers. The intended indication is femal contraception. | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-001546-14 | Sponsor Protocol Number: 292003 | Start Date*: 2006-08-30 |
Sponsor Name:NV Organon | ||
Full Title: A randomized, open-label, comparative trial to evaluate the effects on ovarian function of a monophasic combined oral contraceptive (COC) containing 2.5 mg nomegestrol acetate (NOMAC) and 1.5 mg es... | ||
Medical condition: Hormonal oral contraception in healthy women | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-000041-12 | Sponsor Protocol Number: 49/11/EDG/TP2 | Start Date*: 2012-03-23 | |||||||||||
Sponsor Name:Zentiva k.s. Prague | |||||||||||||
Full Title: Characterisation of ovulation inhibition and effects on metabolic parameters and haemostatic system of multiple administrations of a fixed-dose combination product containing 0.02 mg ethinylestradi... | |||||||||||||
Medical condition: Investigation of ovulation inhibition, effects on metabolic parameters and haemostatic system for indication of contraception | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004296-77 | Sponsor Protocol Number: BTA585-003 | Start Date*: 2016-02-08 |
Sponsor Name:Biota Pharma Europe Limited | ||
Full Title: A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity Against Respiratory Syncytial Virus Infection, and the Pharmacokinetics of Multiple Oral... | ||
Medical condition: Respiratory Syncytial Virus | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-002459-41 | Sponsor Protocol Number: P012-00 | Start Date*: 2012-11-29 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A multicenter, randomized, partially-blinded, Phase IIb dose-finding study on ovarian function, vaginal bleeding pattern, and pharmacokinetics associated with the use of combined vaginal rings rele... | |||||||||||||
Medical condition: This is the dose-finding study on ovarian function, vaginal bleeding pattern, and pharmacokinetics associated with the use of combined vaginal rings in healthy women | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: NO (Completed) DE (Completed) SE (Completed) NL (Completed) HU (Completed) ES (Completed) DK (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002667-14 | Sponsor Protocol Number: UHKT-RLP/2011 | Start Date*: 2011-07-19 | |||||||||||
Sponsor Name:Institute of Hematology and Blood Transfusion | |||||||||||||
Full Title: Effect of vaccination in patients with recurrent respiratory papillomatosis– can we improve the quality of life of these patients? | |||||||||||||
Medical condition: Recurrent respiratory papillomatosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012121-11 | Sponsor Protocol Number: P06060 (299001) | Start Date*: 2009-10-13 | |||||||||||
Sponsor Name:Schering-Plough Research Institute, a Division of Schering Corporation | |||||||||||||
Full Title: A randomized, multicenter, explorative trial to explore the safety, acceptability and vaginal bleeding pattern of three doses of an etonogestrel-releasing medicated intrauterine system (ENG-MIUS) v... | |||||||||||||
Medical condition: healthy parous women in need of contraception | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003075-35 | Sponsor Protocol Number: CTT116855 | Start Date*: 2014-07-24 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: A phase III, 52 week, randomized, double-blind, 3-arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination fluticasone furoate/ umeclidinium/vi... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) FI (Completed) PL (Completed) SE (Completed) DE (Completed) AT (Completed) CZ (Completed) BE (Completed) DK (Completed) ES (Completed) NO (Completed) RO (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006633-41 | Sponsor Protocol Number: 310723 | Start Date*: 2007-04-11 | |||||||||||
Sponsor Name:Bayer Schering Pharma AG | |||||||||||||
Full Title: Monocenter, open-label, randomized study to determine the ovulation inhibitory effect of the combined oral contraceptives SH T04769G (0.015 mg Ethinylestradiol and 1.5 mg Dienogest in a modified re... | |||||||||||||
Medical condition: The aim of this monocenter, open-label, randomized study is to determine the ovulation inhibitory effect of the COC SH T04769G (0.15 mg Ethinylestradiol and 1.5 mg Dienogest in a modified release f... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002350-22 | Sponsor Protocol Number: LR-201 | Start Date*: 2020-01-14 | |||||||||||
Sponsor Name:Chemo Research S.L. | |||||||||||||
Full Title: Multi-center, phase 2, open-label, randomized clinical trial to evaluate the inhibition of ovulation of 3 dosing strengths of levonorgestrel (LNG) vaginal delivery system (VDS), releasing during 28... | |||||||||||||
Medical condition: Women´s healthcare (Contraception, inhibition of ovulation) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-004036-30 | Sponsor Protocol Number: ALS-8176-502 | Start Date*: 2013-11-29 | |||||||||||
Sponsor Name:Alios BioPharma | |||||||||||||
Full Title: A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of Multiple Doses of Orally Administered ALS-008176 Against Respirator... | |||||||||||||
Medical condition: Respiratory Syncytial Virus (RSV) infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002700-14 | Sponsor Protocol Number: NA-0113-200-EU | Start Date*: 2018-12-14 | |||||||||||
Sponsor Name:Navad Life Sciences Pte Ltd | |||||||||||||
Full Title: Single-center, open-label, adaptive design study to evaluate the influence on hormonal and ovarian function and vaginal bleeding pattern of different dosages of levonorgestrel administered once dai... | |||||||||||||
Medical condition: Investigation of ovulation inhibition for indication of contraception | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004042-26 | Sponsor Protocol Number: PrEP-CS-002 | Start Date*: 2015-11-17 | |||||||||||
Sponsor Name:hVIVO Services Limited | |||||||||||||
Full Title: A Phase II, Double-Blinded, Randomised, Controlled Study to Examine the Prophylactic Efficacy, Safety and Tolerability of PrEP-001 in Asthmatic Subjects Subsequently Challenged with Human Rhinoviru... | |||||||||||||
Medical condition: Human Rhinovirus (HRV-16) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002895-26 | Sponsor Protocol Number: PrEP-CS-001 | Start Date*: 2015-09-08 | |||||||||||
Sponsor Name:hVIVO Services Limited | |||||||||||||
Full Title: A Phase II, Repeated Dose, Double-Blinded, Randomised, Controlled Study to Examine the Prophylactic Efficacy, Safety and Tolerability of PrEP-001 in Healthy Subjects Subsequently Challenged with In... | |||||||||||||
Medical condition: Influenza A/Perth/16/2009(H3N2) Virus | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023090-19 | Sponsor Protocol Number: SMR 2375 | Start Date*: 2011-03-29 | |||||||||||
Sponsor Name:AlgiPharma AS | |||||||||||||
Full Title: A double-blind, randomized, placebo-controlled, cross-over study to evaluate the safety, tolerability and preliminary efficacy of alginate oligosaccharide (OligoG) administered for 28 days in subje... | |||||||||||||
Medical condition: Cystic Fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001282-24 | Sponsor Protocol Number: REVCS002 | Start Date*: 2017-06-21 | |||||||||||
Sponsor Name:ReViral Ltd | |||||||||||||
Full Title: A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of Multiple Doses of RV521 Against Respiratory Syncytial Virus infecti... | |||||||||||||
Medical condition: Respiratory Syncytial Virus Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004544-32 | Sponsor Protocol Number: CT-P27/2.1 | Start Date*: 2014-02-10 | |||||||||||
Sponsor Name:Celltrion, Inc | |||||||||||||
Full Title: Randomized, double-blind, placebo-controlled, single-centre, phase IIa study in healthy volunteers to evaluate the efficacy and safety of CT-P27 in an influenza challenge model | |||||||||||||
Medical condition: Influenza | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
